Loading
AB
Adverum Biotechnologies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Fischer Laurent, was filed 08 Dec 2025.
Adverum Biotechnologies, Inc.: what insiders have been doing
This page follows insider dealings at Adverum Biotechnologies, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Redwood City, United States. The group dates from 2006. In the past year (22 October 2025 to 22 October 2026), 33 filings came from 11 insiders.
The record shows 3 purchases on the open market worth €657k, made by 2 insiders, against 4 sales worth €4.0M by 1 insider. Taken together, the sales exceed the purchases by €3.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Leonard Braden Michael filed the largest sale, €1.9M, on 5 December 2025. Among those who bought: 1 senior executive and 1 chief executive.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 8 December 2025, 319 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (3,171 companies, median 24 filings), a count of 33 filings is above the norm. Over the whole record (from 2016), the tally stands at 42 purchases and 42 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
204
Thresholds
n/a
Buy Volume
€8M
42 ops. · all time
Sell Volume
€8M
42 ops. · all time
Who traded when
BuySaleBraden Michael Leonard13 buys4 sales
Laurent Fischer2 buys1 sale
Peter Soparkar1 buy1 sale
Setareh Seyedkazemi1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$861k
Net income-US$112.7M-13092.7% margin
Last declaration on 10 December 2025
Declarations204 total
351,513 sharesCommon StockSEC:0001379344-25-000006:1
25,000 sharesCommon Stock - Restricted Stock UnitsSEC:0001379344-25-000006:2
500,000 shares0Common Stock - Performance Stock UnitsSEC:0001379344-25-000006:3
522,666 sharesCommon Stock - Performance Stock UnitsSEC:0001379344-25-000006:4
8,125 sharesCommon Stock - Restricted Stock UnitsSEC:0001903088-25-000005:1
85,000 shares0Common Stock - Performance Stock UnitsSEC:0001903088-25-000005:2
88,332 sharesCommon Stock - Performance Stock UnitsSEC:0001903088-25-000005:3
61,150 sharesCommon StockSEC:0001321937-25-000005:1
8,125 sharesCommon Stock - Restricted Stock UnitsSEC:0001321937-25-000005:2
42,000 shares0Common Stock - Performance Stock UnitsSEC:0001321937-25-000005:3
42,000 sharesCommon Stock - Performance Stock UnitsSEC:0001321937-25-000005:4
85,000 shares0Common Stock - Performance Stock UnitsSEC:0001814883-25-000005:1
85,000 sharesCommon Stock - Performance Stock UnitsSEC:0001814883-25-000005:2
13,125 sharesCommon Stock - Restricted Stock UnitsSEC:0001736315-25-000006:1
150,000 shares0Common Stock - Performance Stock UnitsSEC:0001736315-25-000006:2
157,333 sharesCommon Stock - Performance Stock UnitsSEC:0001736315-25-000006:3
150,000 shares@ US$4.2075.8% of flowCommon StockSEC:0001379344-25-000006:0
48,750 shares@ US$4.2056.4% of flowCommon StockSEC:0001321937-25-000005:0
8,818 sharesCommon StockSEC:0001311210-25-000004:0
54,874 sharesCommon StockSEC:0001903088-25-000005:0
13,000 sharesCommon StockSEC:0001775323-25-000004:0
80,189 sharesCommon StockSEC:0001736315-25-000006:0
5,000 sharesCommon StockSEC:0001574579-25-000004:0
10,333 sharesCommon StockSEC:0001356950-25-000004:0
8,125 sharesCommon Stock - Restricted Stock UnitsSEC:0001814883-25-000005:0
25 of 204 declarations
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq market in the United States. The company is focused on ocular gene therapy, with a strategy centered on highly prevalent eye diseases that create substantial unmet medical need. Founded in 2006, Adverum is headquartered in Redwood City, California, in the San Francisco Bay Area biotechnology cluster. Its corporate positioning is built around the idea that gene therapy could become a new standard of care for sight-threatening retinal diseases. ([adverum.com](https://adverum.com/wp-content/uploads/Adverum-Corporate-Overview_2025.pdf?utm_source=openai))
Adverum’s business model is essentially pipeline-driven. The company’s proprietary intravitreal platform is designed to deliver durable therapies through a physician’s office setting, aiming to reduce the burden of frequent repeat injections that are currently common in retinal care. Its lead asset is ixoberogene soroparvovec, or Ixo-vec (formerly ADVM-022), a one-time intravitreal gene therapy candidate being developed for neovascular, or wet, age-related macular degeneration (wet AMD). Management has positioned Ixo-vec as a potential long-acting therapy designed to provide sustained aflibercept expression and reduce the treatment burden associated with standard anti-VEGF regimens. ([adverum.com](https://adverum.com/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Adverum operates in a crowded and fast-evolving retinal therapeutics landscape. Standard-of-care anti-VEGF injections remain the commercial benchmark in wet AMD, while multiple biotechnology companies are pursuing longer-duration alternatives, including gene therapy approaches and other sustained-delivery technologies. Adverum’s differentiation lies in its “one-and-done” ambition: if successful, it could offer injection freedom and a structurally different value proposition versus chronic dosing. At the same time, this is a high-risk segment, as clinical efficacy, safety, durability, and regulatory acceptance are all critical gating factors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000155837025002000/ocul-20241231x10k.htm?utm_source=openai))
Recent company milestones have been important. In 2025, Adverum initiated ARTEMIS, its first pivotal Phase 3 trial for Ixo-vec, after reporting prior Phase 2 and long-term follow-up data that the company said supported the program’s potential. In October 2025, Adverum and Eli Lilly announced a transaction under which Lilly agreed to acquire Adverum, adding a major strategic dimension to the investment case. For investors, ADVM should therefore be viewed as a Nasdaq-listed United States biotech story with binary clinical upside, a focused ocular gene-therapy pipeline, and an active M&A overlay. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1501756/000162828025017769/exhibit991_41525pressrelea.htm?utm_source=openai))
